Finland's Bioretec posts 22.5% drop in 2025 net sales, withdraws previous financial targets

Bioretec Oy

13/02/2026 07:41

Overview

Finnish medical device firm's 2025 net sales fell 22.5% yr/yr

EBITDA loss widened significantly in 2025

Company received FDA Breakthrough Device Designation for RemeOs DrillPin

Outlook

Bioretec withdraws previous financial targets, citing unattainable goals

Company aims for net sales exceeding EUR 10 mln by 2028

Bioretec plans to maintain sales margin above 70% during 2026-2028

Result Drivers

DISTRIBUTION MODEL SHIFT - Bioretec transitioned from stocking distributors to a direct distribution model in the U.S., aiming for stronger transparency and predictability in sales

COMMERCIAL EXPANSION - Co re-established its commercial presence in high impact regions, contributing to direct sales revenue growth in the U.S.

R&D INVESTMENT - Increased R&D expenditure, reaching 85.8% of net sales, as part of advancing the RemeOs product line and enhancing innovation

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
EUR 3.52 mln
FY Adjusted EPS
-EUR 0.31
FY EPS
-EUR 0.28
FY Net Income
-EUR 9.48 mln
FY EBITDA
-EUR 8.48 mln


Analyst Coverage

The one available analyst rating on the shares is "sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Bioretec Oy is €0.60, about 43.9% above its February 12 closing price of €0.42

Press Release: ID:nWkr5fW9s7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)